Overview

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Status:
Completed
Trial end date:
2018-09-18
Target enrollment:
Participant gender:
Summary
The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475) works and if there is a difference if the drug is injected in the thigh or in the belly. This study will also help to find out more about the safety of this new drug.
Phase:
Phase 2
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.